VIRONIKA, LLC

Basic Information

3601 Spruce Street
Suite G63
PHILADELPHIA, PA, 19104-4205

Company Profile

n/a

Additional Details

Field Value
DUNS: 808308170
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Development of a Small Molecule Inhibitor for EBV Latent Infection

    Amount: $1,500,000.00

    DESCRIPTION (provided by applicant): The goal of this research program is to develop a novel small molecule inhibitor of latent Epstein-Barr Virus (EBV) infection. EBV is a ubiquitous gamma- herpesvir ...

    SBIR Phase II 2014 Department of Health and Human Services
  2. Development of a Small Molecule Inhibitor for EBV Latent Infection

    Amount: $336,701.00

    DESCRIPTION (provided by applicant): The goal of this SBIR research program is to develop a novel small molecule inhibitor of latent Epstein-Barr Virus (EBV) infection. EBV is a ubiquitous gamma- herp ...

    SBIR Phase I 2012 Department of Health and Human Services
  3. Novel Inhibitors of Latent Epstein Barr Virus Infection

    Amount: $268,700.00

    DESCRIPTION (provided by applicant): The product that will result from this SBIR program, proposed by Vironika and its consortium partner, The Wistar Institute, is a new (the first) small molecule dru ...

    SBIR Phase I 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government